Metastatic (Stage IV) Pancreatic Adenocarcinoma MedDRA version: 19.0 Level: LLT Classification code 10033605 Term: Pancreatic cancer metastatic System Organ Class: 100000004864
Conditions
Interventions
Product Name: 90Y-clivatuzumab tetraxetan
Product Code: 90Y-hPAM4
Pharmaceutical Form: Solution for infusion
INN or Proposed INN: clivatizumab tetraxetan
CAS Number: 1462876-11-4
Current Sponsor code:
Sponsors
Immunomedics, Inc.
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Males or non-pregnant, non-lactating females = 18 years old, able to give signed written informed consent. 2. Histologically or cytologically confirmed adenocarcinoma of the pancreas. 3. Stage IV (metastatic) disease documented by CT imaging (MRI if patient allergic to contrast media) 90Y-clivatuzumab tetraxetan 4. Received at least two prior systemic cytotoxic chemotherapy regimens for unresectable, locally advanced or metastatic disease. 5. At least one of the prior systemic cytotoxic chemotherapy regimens for unresectable, locally advanced or metastatic disease must have contained gemcitabine and have met the following criteria: o Completed at least one cycle of the treatment o Received gemcitabine administered at a minimum dose of 800 mg/m2 per week in the first cycle of treatment o Progressed while receiving this gemcitabine regimen or within 3 months of completing gemcitabine o Progression was documented, ? Preferentially radiologically by tumor growth or new lesions, or by ? Clear symptomatic deterioration supported by at least two of the following clinical criteria: = 10% worsening in KPS or = 1 worsening in ECOG; increasing weakness or fatigue; progressive weight loss; new/worsening pain requiring increased pain medication; new/worsening jaundice, nausea, or vomiting; new/worsening ascites or pleural effusions; other physical or laboratory findings consistent with disease progression. 6. Adequate performance status (Karnofsky Performance Status = 70%) 7. Expected survival = 3 months. 8. Adequate hematology without ongoing transfusional support (hemoglobin = 9g/dL, ANC = 1.5 x 10^9/L, platelets = 100 x10^9/L). 9. Adequate renal and hepatic function (creatinine and bilirubin = 1.5 X IULN; AST and ALT = 2.5 X IULN [= 5.0 x IULN if due to liver metastases]). 10. At least 4 weeks beyond any major surgery or radiotherapy, 2 weeks beyond chemotherapy or other experimental treatments, and with any clinically significant related acute toxicities recovered at study entry to Grade 1 by NCI CTCAE v4.0. Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 440 F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range 0
Exclusion criteria
Exclusion criteria: 1. Patients of childbearing potential sexually active but unwilling to use “double barrier” methods of birth control including male use of a condom with female use of a diaphragm, intrauterine device (IUD), or contraceptive sponge during the study until at least 4 weeks after the last dose of active study drug. 2. History of allergy or hypersensitivity or severe toxicity to any of the study drugs or their incipients 3. Known metastatic disease to the central nervous system, unless previously treated and well-controlled for at least 3 months [defined as clinically stable, no edema, no steroids and stable in 2 scans at least 4 weeks apart] 4. Presence of bulky disease (defined as any single mass > 10 cm in greatest dimension). 5. Patients with Grade = 3 nausea or vomiting, and/or signs of intestinal obstruction. 6. Rapid deterioration during screening prior to randomization, i.e. 10% decrease in KPS, 20% decrease in serum albumin levels, unstable pain symptoms requiring modifications in analgesic management, development of jaundice or symptomatic ascites. Prior external beam irradiation to a field that includes more than 30% of the red bone marrow. 8. Patients with non-melanoma skin cancer, cervical carcinoma in situ, superficial bladder cancer, or other non-invasive malignancy are not excluded, but patients with other prior malignancies must have had at least a 2-year disease-free interval. 9. Patients known to be HIV positive, hepatitis B positive, or hepatitis C positive. 10. Patients with: a. Active coronary artery disease, unstable angina, myocardial infarction, or congestive heart failure present within 6 months. b. Cardiac arrhythmia (other than stable atrial fibrillation) requiring antiarrhythmia therapy, NYHA Class II-IV disease, or prolonged QT/QTc interval. c. Other clinically significant cardiac disease, unless baseline MUGA/2DECHO performed and LVEF is within institutional limits. 11. Moderate-to-severe (Grade = 3) respiratory illness present within 6 months. 12. Infection requiring intravenous antibiotic use within 1 week. 13. Other concurrent medical or psychiatric conditions that, in the Investigator’s opinion, may be likely to confound study interpretation, prevent completion of study procedures and follow-up examinations, or may cause undue risk to the patient
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: Overall Survival (OS);Secondary Objective: Other measurements of overall survival (OS) Safety Clinical benefit (KPS, Weight, FACT-HEP, Quality of Life) Radiologic-based measure of tumor response or progression-free survival ;Primary end point(s): Overall survival (OS), which is defined as the time from the date of randomization until the date of death from any cause. ;Timepoint(s) of evaluation of this end point: any time point | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary end point(s): • OS at 3, 6 and 12 months • OS in clinically important subgroups, including Karnofsky performance status (=90% vs. <90%), extent of disease at study entry, time from initial diagnosis (<median vs. =median), and prior therapies received (2 vs. =2). • Tumor response according to RECIST version 1.1, including objective response rate (the sum of complete response [CR] and partial response[PR] rates) and duration of response. • Progression free survival (PFS). • Clinical benefit analyses including patient weight and Karnofsky performance status. • Quality of life analyses as assessed by the FACT-HEP questionnaire. Safety endpoints: • incidence and severity of adverse events, • incidence of serious adverse events, • safety laboratory tests (hematology and chemistry), •vital signs, • physical examination • and electrocardiogram measurements. ;Timepoint(s) of evaluation of this end point: At 3, 6 and 12 months | — |
Countries
Austria, Belgium, Canada, France, Israel, Poland, Spain, United States
Contacts
Public ContactRegulatoy Submissions
Medpace Germany GmbH
Outcome results
None listed